Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 53

1.

Aspirin for cancer is no mere antiplatelet prototype. There is potential in its ancient roots.

Lawrence JR, Baxter GJ, Paterson JR.

Med Hypotheses. 2016 Sep;94:74-6. doi: 10.1016/j.mehy.2016.07.001. Epub 2016 Jul 5.

2.

Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice.

Mora S, Ames JM, Manson JE.

JAMA. 2016 Aug 16;316(7):709-10. doi: 10.1001/jama.2016.8362. No abstract available.

PMID:
27323335
3.

Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment.

Mora S, Manson JE.

JAMA Intern Med. 2016 Aug 1;176(8):1195-204. doi: 10.1001/jamainternmed.2016.2648. Review.

PMID:
27322595
4.

Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer.

Cao Y, Nishihara R, Wu K, Wang M, Ogino S, Willett WC, Spiegelman D, Fuchs CS, Giovannucci EL, Chan AT.

JAMA Oncol. 2016 Jun 1;2(6):762-9. doi: 10.1001/jamaoncol.2015.6396.

5.

Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis.

Lotrionte M, Biasucci LM, Peruzzi M, Frati G, Giordano A, Biondi-Zoccai G.

Prog Cardiovasc Dis. 2016 Mar-Apr;58(5):495-504. doi: 10.1016/j.pcad.2016.02.001. Epub 2016 Feb 4. Review.

PMID:
26851562
6.

PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.

Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A.

Clin Oncol (R Coll Radiol). 2016 May;28(5):317-26. doi: 10.1016/j.clon.2015.11.008. Epub 2015 Dec 17. Review.

PMID:
26712086
7.

Where Do We Stand With Aspirin for the Prevention of Colorectal Cancer? The USPSTF Recommendations.

Chan AT, Ladabaum U.

Gastroenterology. 2016 Jan;150(1):14-8. doi: 10.1053/j.gastro.2015.11.018. Epub 2015 Nov 18. Review. No abstract available.

PMID:
26602220
8.

Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS).

Fedirko V, Bradshaw PT, Figueiredo JC, Sandler RS, Barry EL, Ahnen DJ, Milne GL, Bresalier RS, Baron JA.

Cancer Prev Res (Phila). 2015 Nov;8(11):1061-8. doi: 10.1158/1940-6207.CAPR-15-0212. Epub 2015 Aug 24.

9.

Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.

Ait Ouakrim D, Dashti SG, Chau R, Buchanan DD, Clendenning M, Rosty C, Winship IM, Young JP, Giles GG, Leggett B, Macrae FA, Ahnen DJ, Casey G, Gallinger S, Haile RW, Le Marchand L, Thibodeau SN, Lindor NM, Newcomb PA, Potter JD, Baron JA, Hopper JL, Jenkins MA, Win AK.

J Natl Cancer Inst. 2015 Jun 24;107(9). pii: djv170. doi: 10.1093/jnci/djv170. Print 2015 Sep.

10.

[Chemoprevention of colorectal cancer for broad clinical use in the future].

Mutoh M, Ishikawa H, Wakabayashi K.

Gan To Kagaku Ryoho. 2015 May;42(5):534-7. Japanese.

PMID:
25981646
11.

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.

Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, Baron JA, Berndt SI, Brenner H, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Casey G, Chang-Claude J, Chanock SJ, Cotterchio M, Duggan D, Figueiredo JC, Fuchs CS, Giovannucci EL, Gong J, Haile RW, Harrison TA, Hayes RB, Hoffmeister M, Hopper JL, Hudson TJ, Jenkins MA, Jiao S, Lindor NM, Lemire M, Le Marchand L, Newcomb PA, Ogino S, Pflugeisen BM, Potter JD, Qu C, Rosse SA, Rudolph A, Schoen RE, Schumacher FR, Seminara D, Slattery ML, Thibodeau SN, Thomas F, Thornquist M, Warnick GS, Zanke BW, Gauderman WJ, Peters U, Hsu L, Chan AT; CCFR; GECCO.

JAMA. 2015 Mar 17;313(11):1133-42. doi: 10.1001/jama.2015.1815.

12.

Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment.

Gala MK, Chan AT.

Clin Cancer Res. 2015 Apr 1;21(7):1543-8. doi: 10.1158/1078-0432.CCR-14-0877. Epub 2014 Dec 11. Review.

13.

Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women.

van Kruijsdijk RC, Visseren FL, Ridker PM, Dorresteijn JA, Buring JE, van der Graaf Y, Cook NR.

Heart. 2015 Mar;101(5):369-76. doi: 10.1136/heartjnl-2014-306342. Epub 2014 Dec 4.

14.

Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study.

Lin CC, Lai MS, Shau WY.

Diabet Med. 2015 Mar;32(3):324-31. doi: 10.1111/dme.12596. Epub 2014 Nov 14.

PMID:
25252097
15.

The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial.

Ishikawa H, Mutoh M, Suzuki S, Tokudome S, Saida Y, Abe T, Okamura S, Tajika M, Joh T, Tanaka S, Kudo SE, Matsuda T, Iimuro M, Yukawa T, Takayama T, Sato Y, Lee K, Kitamura S, Mizuno M, Sano Y, Gondo N, Sugimoto K, Kusunoki M, Goto C, Matsuura N, Sakai T, Wakabayashi K.

Gut. 2014 Nov;63(11):1755-9. doi: 10.1136/gutjnl-2013-305827. Epub 2014 Jan 31.

PMID:
24488498
16.

Screening and primary prevention of colorectal cancer: a review of sex-specific and site-specific differences.

Massat NJ, Moss SM, Halloran SP, Duffy SW.

J Med Screen. 2013;20(3):125-48. doi: 10.1177/0969141313501292. Review.

PMID:
24197771
17.

Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.

Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, Takeyama I, Kawano A, Gondo N, Abe T, Tokudome S, Goto C, Matsuura N, Sakai T.

Cancer Med. 2013 Feb;2(1):50-6. doi: 10.1002/cam4.46. Epub 2013 Feb 3.

18.

Role of aspirin in cancer prevention.

Thorat MA, Cuzick J.

Curr Oncol Rep. 2013 Dec;15(6):533-40. doi: 10.1007/s11912-013-0351-3. Review.

PMID:
24114189
19.

Combination chemoprevention: future direction of colorectal cancer prevention.

Zhou P, Cheng SW, Yang R, Wang B, Liu J.

Eur J Cancer Prev. 2012 May;21(3):231-40. doi: 10.1097/CEJ.0b013e32834dbbfd. Review.

PMID:
22456425
20.

Effect of preventive messages tailored to family history on health behaviors: the Family Healthware Impact Trial.

Ruffin MT 4th, Nease DE Jr, Sen A, Pace WD, Wang C, Acheson LS, Rubinstein WS, O'Neill S, Gramling R; Family History Impact Trial (FHITr) Group.

Ann Fam Med. 2011 Jan-Feb;9(1):3-11. doi: 10.1370/afm.1197.

Supplemental Content

Loading ...
Support Center